IL1B and acute myeloid leukemia: They found that AML-MRC MSCs presented higher IL-6 expression, whereas de novo AML MSCs presented increased expression of VEGFA, CXCL12, RPGE2, IDO, IL-1β, IL-6, and IL-32, and decreased IL-10 expression.